Acrivon Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACRV research report →
About the company
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification.
- CEO
- Peter Blume-Jensen
- IPO
- 2022
- Employees
- 75
- HQ
- Watertown, MA, US
Price Chart
- Market Cap
- $54.28M
- P/E
- -0.86
- P/S
- 0.00
- P/B
- 0.70
- EV/EBITDA
- -0.28
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -64.43%
- ROIC
- -84.09%
- Revenue
- $0 · 0.00%
- Net Income
- $-77,905,000 · 3.29%
- EPS
- $-2.02 · 3.81%
- Op Income
- $-84,114,000
- FCF YoY
- 4.53%
- 52W High
- $3.56
- 52W Low
- $1.20
- 50D MA
- $1.72
- 200D MA
- $1.86
- Beta
- 1.91
- Avg Volume
- 568.96K
Get TickerSpark's AI analysis on ACRV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 20,275 |
| Jun 17, 26 | TOMSICEK MICHAEL JOHN | other | 20,275 |
| Jun 17, 26 | Shacham Sharon | other | 20,275 |
| Jun 17, 26 | Palani Santhosh | other | 20,275 |
| Jun 17, 26 | Magovcevic-Liebisch Ivana | other | 20,275 |
| Jun 17, 26 | DiRocco Derek | other | 20,275 |
| Jun 17, 26 | BAUM CHARLES M | other | 20,275 |
| May 21, 26 | Blume-Jensen Peter | other | 13,729 |
| May 18, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 9,366 |
| May 18, 26 | TOMSICEK MICHAEL JOHN | other | 9,366 |
Our ACRV coverage
Recent articles, reports, and earnings notes.
No research on ACRV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACRV report →Similar companies
Peers in the same neighborhood.